=============================================================== == == == ----------- ALS INTEREST GROUP ----------- == == ALS Digest (#58, 25 September 1993) == == amyotrophic lateral sclerosis / motor neurone disease == == == == To subscribe, to unsubscribe, to contribute notes, == == etc. to ALS Digest, please send e-mail to: == == bro@huey.met.fsu.edu (Bob Broedel) == == == == All interested people may "broadcast" messages to == == ALS Digest subscribers by sending to: == == als@huey.met.fsu.edu == == == == Back issues are available via e-mail from: == == LISTSERV@mailer.fsu.edu == == == =============================================================== Though I have a lot of information, this issue will be very short because I will be out of town for a while (leaving tomorrow to take my wife to CNTF clinical trial). Sincerely, Bob Broedel (1) ===== building the ALS e-mail network ========== Date : 07 Sep 93 16:09:50 EDT >From : Greg Trautman <72262.1664@CompuServe.COM> Subject: ALS Digest/Interest Group I would like to subscribe to the ALS Digest. At present I am providing long term in home health care to people with ALS. A couple of the people I am helping are using augmentative communications devices. One of my goals is to use the computer, modem and online services to motivate these bright yet physically disabled people to actively participate in and contribute to society. Thanks, Greg Trautman (72262.1664@compuserve.com) (2) ===== another useful drug ? ========== TI Technology Available for License or Transfer--Neurology. SO Healthcare-Technology-Business-Opportunities, 930800, August 00, 1993, VOLUME 14, ISSUE 8. YEAR 1993. PU Biomedical Business International. AV Subscription: $325 per year as of 1/92. Published monthly. Contact Biomedical Business International, 1524 Brookhollow Drive, Santa Ana, CA 92705. Phone (714) 755-5757. FAX (714) 755-5704. A potential treatment involving the therapeutic use of amodiaquin, a single agent that embodies properties of potential significance for the treatment of Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis and related disorders is available for license or transfer. Administration of amodiaquin in an effective amount enhances nerve function and decreases undesirable autoimmune reactions. Amodiaquin appears unique in its ability, as a single agent, to perform these varied functions at the same sites and at the same time. Reference number: ROB8912. Contact: Emily E. Waldron, Technology Transfer Manager, City of Hope National Medical Center, 1500 E. Duarte Rd., Duarte, CA 91010, USA; telephone 818/301-8829; fax 818/301-8175. == end of als 58 ==